# Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations

> **NCT02214615** · PHASE4 · COMPLETED · sponsor: **VA Connecticut Healthcare System** · enrollment: 2 (actual)

## Conditions studied

- Erythromelalgia

## Interventions

- **DRUG:** Carbamazepine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02214615
- **Lead sponsor:** VA Connecticut Healthcare System
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2017-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02214615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02214615, "Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02214615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*